Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica

Evaluation of the Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica and Comparison With Others Inflammatory Rheumatic Diseases.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06558357

Acronym

RHUMATEP

Enrollment

210

Registered

2024-08-16

Start date

2024-09-01

Completion date

2024-12-31

Last updated

2024-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

18-FDG, Inflammatory Rheumatism, Positron-emission Tomography

Keywords

Polymyalgia rheumatica, FDG, PET, Diagnostic performance, score

Brief summary

Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.

Detailed description

Polymyalgia Rheumatica is difficult to diagnostic because symptoms are non specific and many diseases can be differential diagnosis (cancer, infections, others rheumatisms...). PET-CT is more often used to help for diagnostic of inflammatory disease, and particularly inflammatory rheumatism. Some scores have been described to harmonize the diagnosis of Polymyalgia rheumatica. The aim of this study is to evaluate the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and compared with others inflammatories diseases such as ankylosing spondylarthritis. This is a multicentric retrospective study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 110 Years

Healthy volunteers

Inclusion criteria

* Having 18-FDG PET-CT between 2012 and 2024 * Diagnosis of inflammatory rheumatism by specialist doctor * Adult without opposition to use there data for research * Affiliate to social security system

Exclusion criteria

* Refusal participation * Patient under juridic protection

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic performance of 18-FDG PET scores for diagnostic of Polymyalgia rheumatica.	up to 9 months	Evaluation of the metabolism of mains joints compared to liver. Calculation of different scores described in literature.

Secondary

Measure	Time frame	Description
Analysis of SUV and visual fixation of mains joints.	up to 9 months	Measure of SUV of mains joints and evaluation of the fixation compared to liver.
Diagnostic performance of 18-FDG PET scores for diagnostic of others inflammatory rheumatism.	up to 9 months	Evaluation of the precedent scores for diagnosis of others rheumatisms. Creation of others scores if some joints seem to be interesting.
Comparaison of scores with clinical, biological and radiological data.	up to 9 months	Search for correlation between scores and symptoms, blood test or CT/MRI exams.

Countries

France

Contacts

Primary ContactSolène QUERELLOU

solene.querellou@chu-brest.fr0298223080

Backup ContactChloé QUERE

chloe.quere@chu-brest.fr

Outcome results